Silverback Therapeutics

While the firm does not publicly disclose a specific focus, its name and industry context suggest a concentration in biotechnology, particularly targeted therapies such as antibody-drug conjugates or immuno-oncology. The multi-office structure implies a broad mandate rather than a single-drug pipeline.

The firm's classification is not publicly specified. Its five-office footprint and biotech orientation suggest it may function as a single-family office or a specialized asset manager. Without disclosed principals or AUM, a definite categorization is not possible.

Deployment details are not publicly available. The firm likely invests in biotechnology companies or therapeutic assets, possibly through direct equity, venture funding, or partnership structures. No portfolio companies, deal sizes, or fund structures have been confirmed.

The wealth origin is not disclosed. The firm may be backed by a single affluent family or a group of investors, given its private nature and lack of public fundraising. No sources attribute it to a specific fortune or family.

Silverback Therapeutics is not a publicly traded company; it appears to be a privately held investment entity. Its website and office network indicate it manages capital for investment purposes rather than operating as a drug-development company with a public stock.

The specific functions of these offices are not described. Zurich suggests a European base for sourcing deals or investor relations, while Boston aligns with the US biotech cluster. The New Canaan and Seattle offices may serve as regional hubs for deal sourcing or operational support.

No public records of specific investments or portfolio companies have been identified. The firm's investment activity remains private, possibly due to its structure as an unregistered vehicle that does not require public disclosures.